IP Library Granted Patent US 8,734,428
Granted Patent B2
US 8,734,428 · App. 13/477,657 · Granted May 27, 2014

Insulin pump having selectable insulin absorption models

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,734,428
App. No.
13/477,657
Granted
May 27, 2014
Kind
B2
Abstract

Methods of estimating human insulin absorption for use in an insulin pump are disclosed. A method includes prompting a user to select between a first insulin absorption model and a second insulin absorption model. The method also includes prompting a user to provide at least one model parameter. The method further includes forming an applied insulin absorption model from the selected insulin absorption model and the at least one model parameter.

Claims (139)

1. A method of estimating human insulin absorption for use in an insulin pump, the method comprising:

prompting a user to select between a first insulin absorption model and a second insulin absorption model on a user interface associated with an insulin pump;

prompting a user to input at least one model parameter on the user interface; and

forming an applied insulin absorption model operable with the pump from the selected insulin absorption model and the at least one model parameter, the applied insulin absorption model used to estimate a remaining amount of insulin in the user's body at a given time after insulin has been delivered to the user.

2. The method of claim 1 , further comprising employing the applied insulin absorption model to calculate an insulin level of the user.

3. The method of claim 2 , wherein employing the applied insulin absorption model to calculate the insulin level of the user includes applying the equation Current IOB=Initial Bolus Amount * (Total Time Start+time−Elapsed Time) Duration of Activity.

4. The method of claim 1 , wherein the first insulin absorption model is linear.

5. The method of claim 1 , wherein the second insulin absorption model is nonlinear.

6. The method of claim 1 , further comprising providing a third insulin absorption model, t Therein the third insulin absorption model is a customizable insulin absorptions nodal.

7. The method claim 1 wherein the at least one parameter includes a start time.

8. The method of claim 1 , wherein the at least one parameter includes a tail time.

9. The method of claim 8 , further comprising employing the applied insulin absorption model to calculate an insulin level of the user within the tail time by employing the equation

Current

IOB

=

0.05

*

Initial

Bolus

Amount

*

(

Elapsed

Time

Since

Tail

Time

Started

)

Total

Tail

Time

.

10. The method of claim 8 , further comprising employing the applied insulin absorptions model to calculate an insulin level of the user within the tail time by employing the equation

Current

IOB

=

Tail

Threshold

%

*

Initial

Bolus

Amount

*

(

Elapsed

Time

Since

Tail

Time

Started

)

Total

Tail

Time

.

11. The method of claim 1 , wherein the at least one parameter includes a duration.

12. The method of claim 1 , wherein prompting the user to select between the first and second insulin absorption models is performed by the insulin pump.

13. The method of claim 1 , wherein prompting to user to select between the first and second insulin absorption models is performed by a computer interfaced with the insulin pump.

14. The method of claim 2 , wherein the insulin level is a current insulin level of the user at a time that the insulin level is calculated.

15. The method of claim 1 , further comprising modifying the applied insulin absorption model based on user entered data.

16. The method of claim 15 , wherein the user entered data is selected from a group consisting of:

age;

weight;

sex:

type of insulin;

fitness level; and

body mass index.

17. The method of claim 1 , further comprising modifying the applied insulin absorption model based on non-user entered data.

18. The method of claim 17 wherein the non-user entered data includes bolus size.

19. An insulin pump comprising:

a pump mechanism;

a memory configured to store a first insulin absorption model, a second insulin absorption model, and at least one model parameter;

a programmable circuit arranged to control the pump mechanism and operatively connected to the memory, the programmable circuit programmed to:

prompt a user to select between the first insulin absorption model and the second insulin absorption model on a user interface associated with the insulin pump;

prompt a user to provide the at least one model parameter on the user interface; and

form an applied insulin absorption model operable with the pump from the selected insulin absorption model and the at least one model parameter, the applied insulin absorption model used to estimate a remaining amount of insulin in the user's body at a given time after insulin has been delivered to the user.

20. The insulin pump of claim 19 , wherein the programmable circuit is further programmed to employ the applied insulin absorption model to calculate an insulin level of the user.

21. The insulin pump of claim 19 , wherein employing the applied insulin absorption model to calculate the insulin level of the user applies the equation Current IOB=Initial Bolus Amount * (Total Time+Start Time−Elapsed Time) Duration of Activity.

22. The insulin pump of claim 19 , wherein the at least one model parameter includes a start time.

23. The insulin pump of claim 19 , wherein the at least one model parameter includes a tail time.

24. The insulin pump of claim 19 , wherein at least one model parameter includes a duration.

25. The insulin pump claim 19 , wherein the first insulin absorption model is linear.

26. The insulin pump of claim 19 , wherein the second insulin absorption model is nonlinear.

27. The insulin pump of claim 19 , wherein the programmable circuit is further programmed to modify the applied insulin absorption model based on user en entered data.

28. The insulin pump of claim 19 , wherein the programmable circuit is further programmed to modify the applied insulin absorption model based on non-user entered data.

29. A method of estimating human insulin absorption for use in an insulin pump, the method comprising:

prompting at user to select between a linear insulin absorption model and a nonlinear insulin absorption model on a user interface associated with an insulin pump;

prompting a user to input a duration of insulin absorption on the user interface;

prompting a user to input a start time on the user interface;

prompting a user to input a tail time on the user interface;

forming an applied insulin absorption model operable with the insulin pump from the selected insulin absorption model, the duration, the start time, and the tail time;

employing the applied insulin absorption model to calculate an insulin level of the user at a time after insulin has been delivered to the user.

30. The method of claim 29 , wherein prompting the user to select between the linear insulin absorption model and the nonlinear insulin absorption model is performed by the insulin pump.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2018
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II L.P. - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.
To: TANDEM DIABETES CARE, INC.
Reel/Frame 046761/0843 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2018
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II L.P. - PARALLEL FUND "A" L.P.
To: TANDEM DIABETES CARE, INC.
Reel/Frame 046763/0268 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Apr 4, 2014
From: TANDEM DIABETES CARE, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.
Reel/Frame 032608/0780 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Dec 26, 2012
From: TANDEM DIABETES CARE, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.
Reel/Frame 029529/0886 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2012
From: SMITHS MEDICAL ASD, INC.
To: TANDEM DIABETES CARE, INC.
Reel/Frame 029121/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2012
From: BLOMQUIST, MICHAEL L.
To: SMITHS MEDICAL MD, INC.
Reel/Frame 028686/0681 →
MERGER Recorded Jul 31, 2012
From: SMITHS MEDICAL MD, INC.
To: SMITHS MEDICAL ASD, INC.
Reel/Frame 028689/0474 →